Issued on behalf of Aleen Inc.
VANCOUVER – Baystreet.ca News Commentary – The artificial intelligence in healthcare market is projected to expand from $17.2 billion in 2025 to $77.2 billion by 2035 as digital transformation and data-driven medical systems reshape how patients access care[1]. A strategic intelligence report released in November highlights how integrating AI and bioinformatics enables healthcare providers to predict disease risks, personalize treatment plans, and improve patient outcomes through tailored approaches[2]. Within the clinical healthcare AI sector, companies developing tools for early disease detection, predictive analytics, and drug discovery — including WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF), HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF), Tempus AI, Inc. (NASDAQ: TEM), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) — continue to gain momentum as demand for advanced medical technologies accelerates. In parallel, non-medical wellness platforms such as Aleen Inc. (CSE: ALEN-U) operate in a separate category, focusing solely on general well-being insights rather than clinical or diagnostic functions.
Menlo Ventures surveyed 700+ healthcare executives and projects healthcare-specific AI solutions generating $600 million in 2025 will experience dramatic year-over-year growth as ambient scribing, predictive analytics, and clinical decision support gain production-level adoption[3]. The convergence of AI with wearable devices and telehealth platforms enables hyper-personalized care and real-time monitoring, creating favorable timing for companies delivering intelligent wellness ecosystems and precision medicine infrastructure before major institutional waves reshape healthcare delivery[4].
Aleen Inc. (CSE: ALEN-U), a Canadian digital wellness company, has announced it is advancing development of its Smart Analytics feature, designed to help users interpret wellness data clearly and responsibly. The system transforms raw information into structured, accessible insights, emphasizing transparency and personal reflection to encourage users to observe patterns rather than interpret them medically.
"Our current focus is on understanding how an analytical tool can responsibly support everyday well-being, while staying entirely outside the realm of diagnostic or medical functions," said Anastasiia Kalashnik, PR Specialist of Aleen. “We are laying the groundwork for a feature that inspires awareness and self-reflection, not prescribes actions."
The company previously announced the development of a personal account system designed to redefine how individuals interact with their wellness data. The upcoming personal account will serve as an intuitive hub where users can seamlessly upload, manage, and visualize their non-medical well-being information. The Smart Analytics feature now in full-scale development will work in conjunction with these personal accounts to provide users with deeper understanding of their general wellness patterns.
Before that, Aleen announced it was beginning early concept testing for smart wellness analytics, with research highlighting three recurring user expectations: clear visualization of personal wellness patterns, strong privacy safeguards and control over shared information, and simple, non-medical interpretation of structured inputs.
Based in Ontario, Aleen went public in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The company operates in a rapidly expanding market, with the global digital wellness sector currently valued at approximately $12.87 billion in 2025 and projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen is positioned to capture a portion of this expanding demand.
The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen Inc.'s technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access.
Looking ahead to 2026, Aleen plans to launch the personal user accounts currently in development alongside the smart analytics features being tested. With 12,643,300 common shares currently issued and outstanding, Aleen continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman. The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities.
CONTINUED… Read this and more news for Aleen Inc. at: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) reported strong organic growth with Canadian Patient Services revenue exceeding $110 million in Q3 2025, reflecting 41% year-over-year growth driven by 10% same-clinic growth across WELL Medical Centres and 16% across WELL Diagnostics Centres. The company achieved 92% digitization for all primary care clinics in its network for longer than nine months, implementing core features including online patient booking, self-check-in, patient reminders, and digital consents.
"We take clinic transformation very seriously and have a highly methodical way of approaching our digitization plans," said Jeremy Mickolwin, VP of Clinic Operations of WELL. "Our goal is to ensure that every clinic in our network has achieved its 'core digitization' within a year of operations. Our definition of 'core' will likely expand as our new AI enabled applications are being rapidly deployed and driving significant new benefits for providers."
Since announcing 45,000 new primary care patient openings across three provinces in June 2025, WELL has filled 25,000 of these positions as of October 31, 2025, with full satisfaction expected by end of Q1 2026. The company's continued physician recruitment efforts have created additional availability across its network, enabling expanded access to timely primary care while supporting 270,000 new yearly patient visits from this cohort alone.
HEALWELL AI Inc. (TSX: AIDX, OTCQX: HWAIF) achieved record Q3 revenue growth of $30.4 million in Q3-2025, representing a 354% increase compared to $6.7 million in Q3-2024, driven largely by the Orion Health acquisition. The company reported positive Adjusted EBITDA of $0.7 million compared to a loss of $2.8 million in the prior year quarter, marking its second consecutive quarter of positive Adjusted EBITDA and representing approximately 125% year-over-year improvement, while the AI segment delivered approximately 79% revenue growth.
"We are pleased to report HEALWELL's second consecutive quarter of positive Adjusted EBITDA, underscoring the strong execution of our growth strategy and the improving financial performance of our business," said James Lee, CEO of HEALWELL. "Building on this momentum, our recent strategic divestments allow us to sharpen our focus on becoming a pure-play AI and SaaS healthcare company. These steps strengthen our balance sheet, accelerate the commercialization of our AI solutions, and give us more time and resources to further develop our AI and healthcare software, delivering advanced preventative care technologies to health systems globally."
During Q3-2025, HEALWELL acquired the remaining 49% interest in Pentavere Research Group Inc., gaining full ownership of the AI company and strengthening its AI segment with Pentavere's DARWEN™ platform for early disease detection. The company closed the quarter with $15.6 million in cash, and subsequent divestments including the sale of its Polyclinic Family Medicine and Specialty Clinics, the sale of its majority interest in Mutuo Health Solutions, and the formation of a 50/50 clinical research joint venture with WELL Health Technologies Corp. added an additional $9.4 million to further strengthen the balance sheet.
Tempus AI, Inc. (NASDAQ: TEM) launched its first study with a nonprofit foundation collaborator, partnering with the Institute for Follicular Lymphoma Innovation (IFLI) to advance research in follicular lymphoma, which accounts for approximately 10-20% of all non-Hodgkin lymphoma cases in the U.S. The multi-year study will enroll FL patients to generate a comprehensive, multi-omic dataset using next generation sequencing, proteomics, and methylation analysis to facilitate precision medicine and biomarker discovery for a disease where about 20% of patients experience progressive disease within two years of initial treatment.
"This collaboration with IFLI signifies our shared commitment to generating rich, multimodal datasets that can help transform research for this specific patient population," said Kate Sasser, PhD, Chief Scientific Officer of Tempus. "This comprehensive approach will provide researchers with a uniquely deep and actionable understanding of follicular lymphoma, paving the way for new discoveries and personalized treatment strategies."
This study builds on Tempus and IFLI's existing collaboration to create a consolidated, real-world FL data library, with the companies aiming to accelerate the discovery of new insights and support the development of innovative therapies. By integrating real-world clinical data with advanced molecular profiling, the partnership seeks to enhance outcomes for FL patients worldwide while contributing critical insights to inform the development and validation of comprehensive whole genome sequencing approaches.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) achieved a $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for neurological diseases—bringing the company's total milestone and upfront payments across all partnerships and collaborations to over $500 million. The clinical stage TechBio company reported third quarter 2025 total revenue of $54.3 million, up 54% year-over-year, with software revenue of $40.9 million (up 28%) and drug discovery revenue of $13.5 million compared to $3.4 million in the prior year period, supported by approximately $785 million of cash and cash equivalents as of October 9, 2025, providing runway through the end of 2027.
"Recursion continues to deliver on our internal pipeline, our strategic partnerships and the continued building and refinement of the Recursion OS. On the partnership front, we are proud to announce that with the option of our second neuro map in the Roche and Genentech collaboration, we've achieved over $500 million in upfront and milestone payments from our partners to date as we continue to deliver novel insights and advance programs for some of the toughest disease areas," said Chris Gibson, Co-Founder and CEO of Recursion. "This is only the beginning of the returns we expect to see on the investment in our platform. With a strong cash runway through the end of 2027, we look forward to delivering on our pipeline and proving that building an end-to-end AI-enabled platform—combining massive proprietary datasets with industry-leading supercomputing capabilities and sophisticated AI models—is the critical infrastructure we need to realize real change in our industry."
The company's internal pipeline includes REC-617, a CDK7 inhibitor in the ELUCIDATE Phase 1/2 trial that established a maximum tolerated dose of 10 mg once-daily with one confirmed partial response and five cases of stable disease among 29 heavily pre-treated patients, now expanding into second-line-plus platinum-resistant ovarian cancer, and REC-7735, a newly nominated PI3Kα H1047R inhibitor development candidate entering IND-enabling studies with preclinical data demonstrating significant tumor regressions and greater than 100-fold selectivity over wild-type PI3Kα.
Recursion is well on track for over $100 million in milestone payments by the end of 2026, with multiple neuroscience target validation programs advancing through partnerships with Roche and Genentech (having achieved $213 million in upfront and milestones to date across a 10-year collaboration for up to 40 programs) and Sanofi (having achieved $130 million in upfront and milestones to date for up to 15 programs across oncology and immunology), while additional data from REC-4881 in the Phase 2 TUPELO study for familial adenomatous polyposis is expected in December 2025.
Article Sources: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/
CONTACT:
Baystreet.ca
[email protected]
(805) 649-0042
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval. The platform provides wellness insights based on user inputs and is not intended to diagnose, treat, or prevent any medical condition.
--
SOURCES CITED:
1. https://orthospinenews.com/2025/11/07/artificial-intelligence-in-healthcare-market-to-surge-across-usa-europe-apac-and-saudi-arabia-by-2035/
2. https://www.globenewswire.com/news-release/2025/11/25/3194434/28124/en/Precision-Medicine-Strategic-Intelligence-Report-2025-Opportunities-in-Integrating-AI-and-Bioinformatics-to-Predict-Disease-Risks-Enhance-Diagnostics-and-Shape-Personalized-Care.html
3. https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/
4. https://www.bcg.com/publications/2025/digital-ai-solutions-reshape-health-care-2025
